DEVELOP OF ANTIBODY FRAGM AS CONTR AGT FOR MRI OF ALZH?S DIS AMYLOID PLAQUES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 将治疗或诊断蛋白靶向神经系统的能力受到血-脑/神经屏障的存在的限制。在这个项目中，我们正在测试这样一个假设，即针对纤维状人Aé42的单抗(IgG4.1)的F(AB2)2片段的修饰可以用于使用高场强磁共振显微成像(MRMI)(9.4T)对阿尔茨海默病(AD)中的淀粉样斑块进行分子成像。这种造影剂在AD转基因小鼠体内成像斑块的能力可能会导致人类早期诊断AD，也提供了目前正在开发的抗淀粉样蛋白疗法的疗效的直接衡量标准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ability to target therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain/nerve barriers. In this project we are testing the hypothesis that modifications of an F(ab2)2 fragment of a monoclonal antibody (IgG4.1) against fibrillar human A¿42 can be used for the molecular imaging of amyloid plaques in Alzheimer's disease (AD) using high field strength magnetic resonance microimaging (MRMI) (9.4 T). The ability of this contrast agent to image plaques in vivo in AD transgenic mice may lead to early diagnosis of AD in humans and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.